At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 13, 2026 at 16:02 ET
Inhibrx Biosciences reported Q3 2026 net loss of $38.7M ($2.46 per share), wider than the $35.3M loss in Q3 2025, with $2.0M in license fee revenue from Pfizer. The company highlighted upcoming clinical milestones for ozekibart in chondrosarcoma and Ewing sarcoma, and ordastobart in HNSCC and NSCLC, with cash of $199.5M funding operations into 2027.
- Net loss of $38.7M ($2.46 per share) vs $35.3M ($2.28) in Q3 2025
- Revenue of $2.0M from Pfizer license fee, vs $0 in Q3 2025
- Cash and equivalents $199.5M as of Sep 30, 2026, up from $124.2M at Dec 31, 2025
- R&D expense $26.0M, down from $28.5M; G&A $7.8M, up from $5.3M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access